NORMAN, OKLA. – Eight proposals have been funded by the Strategic Equipment Investment Program from the Office of the Vice President for Research and Partnerships. Equipment purchased under this program is expected to advance research and creative activities at the University of Oklahoma.
This program supports the purchase of strategic equipment that enhances a team’s capabilities and competitiveness at a national level, specifically, the equipment is expected to “provide new opportunities for advancing the team’s ability to achieve new goals in terms of creativity, discovery, innovation, and competitiveness in securing external funding.”
The funded proposals are:
This is the seventh offering of the Strategic Equipment Investment Program. Proposals from Spring 2024 SEIP initiatives accounted for $4.5 million in new extramural funding. Learn more about SEIP and other internal seed funding opportunities at ou.edu/research.
About the University of Oklahoma
Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. For more information about the university, visit www.ou.edu.
Robin Zape-tah-hol-ah Starr Minthorn (Kiowa), professor and chair of the Department of Educational Leadership and Policy Studies in the University of Oklahoma Jeannine Rainbolt College of Education, has been elected president of the Association for the Study of Higher Education (ASHE) — becoming the first Indigenous person to hold this role in the organization’s history.
A new study from the University of Oklahoma suggests that small genetic differences in two proteins – previously known for their role in premature infants’ lungs – may also influence how their eyes develop, potentially affecting the risk of retinopathy of prematurity (ROP).
University of Oklahoma researcher Elizabeth Wellberg, Ph.D., is the senior author of a review article in The Journal of Clinical Investigation that gathers current research evidence about the effects of GLP-1 drugs, like Ozempic and Zepbound, on cancer risk.